肿瘤微环境与乳腺癌HER2靶向治疗耐药研究进展  

Progression on relationship between tumor microenvironment and HER2 targeted drug resistance in breast cancer

作　　者：朱佳钰 张清媛[1] ZHU Jiayu;ZHANG Qingyuan(Department of Oncology,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China.)

机构地区：[1]哈尔滨医科大学附属肿瘤医院肿瘤内科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2024年第15期2909-2914,共6页Journal of Modern Oncology

摘　　要：肿瘤微环境为肿瘤细胞提供赖以生存的条件,参与恶性肿瘤的发生发展,并在肿瘤耐药中发挥重要作用。抗HER2靶向药物的问世在HER2阳性乳腺癌治疗领域中具有里程碑意义,然而不容忽视的耐药问题影响持续的临床获益。目前已认识到肿瘤微环境成分可作为乳腺癌抗HER2疗效预测指标并参与HER2靶向治疗耐药。本文就肿瘤微环境中成纤维细胞、脂肪细胞、免疫细胞及细胞因子参与HER2靶向耐药治疗机制以及针对微环境成分增强抗HER2疗效的研究进展进行综述。Tumor microenvironment provides survival conditions for tumor cells and participates in the invasion and metastasis of malignant tumors.It is highly heterogeneous,dynamic and immunosuppressive.The emergence of anti-HER2 therapy is a milestone in the field of HER2 positive breast cancer treatment.However,the problem of drug resistance can not be ignored,which affects the continuous clinical benefits.It has been recognized that elements of tumor microenvironment can be used as predictors of anti-HER2 therapies in breast cancer as well as play an important role in HER2 targeted drug resistance.We reviewed the mechanism of fibroblasts,adipocytes,immunocytes and cytokines involved in HER2 targeted drug resistance in tumor microenvironment,and the research progression of targeting microenvironment components in the treatment of HER2-positive breast cancer.

关 键 词：乳腺癌 人表皮生长因子受体2 肿瘤微环境 

分 类 号：R737.9[医药卫生—肿瘤]